Proactive Investors - Run By Investors For Investors

MGC Pharmaceuticals aims to develop new medicinal cannabis strains

The new research builds on the company’s existing programs in Europe.
MGC Pharmaceuticals aims to develop new medicinal cannabis strains
MGC is targeting first sales by Q3 2017

MGC Pharmaceuticals (ASX:MXC) has signed an agreement with the University of Ljubljana in Slovenia to commence a 3-year comprehensive botanical research program.

The goal of the research program is to create medicinal cannabis strains tailored for specific medical indications, including epilepsy, chronic pain, as well as the side effects of cancer.

MGC’s shares were last trading 16% higher intra-day on Monday, at $0.05.

To facilitate the research program, the biotechnical faculty of the university has been granted a full medical cannabis license from the Ministry of Health of the Republic of Slovenia.

The license allows the faculty to grow and conduct botanical research with MGC Pharmaceuticals in Slovenia for all strains of CBD and THC medical cannabis.

The research program will focus on developing new, improved varieties from MGC’s proprietary strains and to develop efficient cannabis breeding methods based on modern scientific approaches.

The results of the research are expected to yield new genetic intellectual property relating to medicinal cannabis strains.  The new varieties will be registered in the European Union.

It is likely that when medicinal cannabis is legalised in European countries for medical purposes, only registered varieties of medical cannabis will be allowed to be cultivated.

The new intellectual property is expected to give MGC a competitive advantage for future breeding programs and its ongoing growing operations in Europe.

The new research builds on the company’s existing medicinal cannabis research program being conducted in the Czech Republic.

MGC is targeting full commercialisation and first sales of its DermaPlus product range in Europe by Q3 2017, for the relief of irritated/inflamed skin conditions due to acne, seborrhea or psoriasis.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MXC profile View Profile

MGC Pharmaceuticals Ltd Timeline

Related Articles

cannabis leaf and green tablets
October 30 2018
The company will now proceed with stage II of the human clinical trial.
The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 31 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth
High Hampton Holdings set to add near term revenue to bottom line with Mojave Jane acquisition
November 13 2018
Mojave Jane is a California-licensed manufacturer of premium cannabis extracts and concentrates for buyers in the US state

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use